Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$22.02
+2.1%
$20.66
$13.40
$25.23
$3.68B0.641.98 million shs869,394 shs
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
$33.93
-2.6%
$29.34
$16.54
$38.93
$948.77M0.42193,315 shs511,211 shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$31.72
+1.4%
$30.51
$21.51
$56.00
$3.80B0.911.38 million shs2.18 million shs
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$46.99
$46.63
$28.21
$62.00
$3.54B0.682.59 million shsN/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
+2.62%+1.55%-3.27%+52.87%+25.92%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
+11.03%+12.47%+11.53%+87.81%+87.10%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
+6.91%+6.51%-4.26%+29.70%-22.54%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
0.00%0.00%+0.51%+36.48%+22.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
4.6806 of 5 stars
4.43.00.00.03.34.22.5
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
0.9906 of 5 stars
3.60.00.00.00.60.80.0
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
2.4674 of 5 stars
4.50.00.00.03.30.80.0
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
1.6334 of 5 stars
3.12.00.00.02.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.71
Moderate Buy$27.8826.59% Upside
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
3.17
Buy$46.6037.36% Upside
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3.06
Buy$65.35106.02% Upside
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
2.13
Hold$52.5711.88% Upside

Current Analyst Ratings Breakdown

Latest LENZ, SWTX, RNA, and ACAD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$55.00
6/27/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$96.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $22.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$37.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
6/24/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$50.00
6/23/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$26.00 ➝ $38.00
6/17/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
6/11/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageStrong-Buy$65.00
6/10/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$70.00 ➝ $75.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$957.80M3.85$0.74 per share29.82$4.40 per share5.00
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/A$7.42 per shareN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$10.90M350.75N/AN/A$11.94 per share2.66
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$191.59M18.48N/AN/A$6.47 per share7.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$226.45M$1.3716.0728.974.5322.97%17.46%10.75%8/5/2025 (Estimated)
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$49.77M-$1.77N/AN/AN/AN/A-23.74%-22.65%8/13/2025 (Estimated)
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$322.30M-$3.00N/AN/AN/A-4,136.00%-26.96%-24.57%8/8/2025 (Estimated)
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$258.13M-$3.41N/AN/AN/A-115.60%-51.10%-43.80%8/6/2025 (Estimated)

Latest LENZ, SWTX, RNA, and ACAD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$0.81N/AN/AN/A$73.39 millionN/A
8/5/2025Q2 2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.14N/AN/AN/A$263.07 millionN/A
5/9/2025Q1 2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$0.81-$1.11-$0.30-$1.11$64.19 million$49.09 million
5/8/2025Q1 2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million
5/7/2025Q1 2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.10$0.11+$0.01$0.11$239.32 million$244.32 million
5/7/2025Q1 2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$0.55-$0.53+$0.02-$0.53N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/AN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/AN/AN/AN/AN/A
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
2.88
2.80
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/A
23.09
23.09
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
16.91
16.91
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/A
4.33
4.18

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
54.32%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510167.36 million123.01 millionOptionable
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
11028.15 million26.20 millionN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
190120.52 million115.90 millionOptionable
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
23075.35 million69.45 millionOptionable

Recent News About These Companies

Biotech Stocks To Consider - June 16th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.02 +0.45 (+2.09%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

LENZ Therapeutics stock logo

LENZ Therapeutics NASDAQ:LENZ

$33.92 -0.90 (-2.57%)
As of 03:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Avidity Biosciences stock logo

Avidity Biosciences NASDAQ:RNA

$31.72 +0.45 (+1.45%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

SpringWorks Therapeutics stock logo

SpringWorks Therapeutics NASDAQ:SWTX

$46.99 0.00 (0.00%)
As of 07/1/2025

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.